Processa Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0 | $0 |
| Research and development | $7.8M | $7.3M | $5.8M | $11.5M | $6.9M |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M |
| Interest expense | — | — | — | — | $362 |
| Pretax income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$12.0M |
| Income tax expense | — | — | — | — | -$530,611 |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$11.4M |
| Balance Sheet | |||||
| Cash and equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M |
| Current assets | $5.7M | $1.9M | $5.6M | $8.4M | $18.3M |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M |
| Current liabilities | $2.2M | $1.5M | $730,579 | $998,556 | $971,020 |
| Total liabilities | $2.2M | $1.5M | $797,484 | $1.1M | $978,405 |
| Stockholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M |
| Depreciation and amortization | $1,204 | $782 | $222 | — | $484 |
| Stock-based compensation | $857,550 | $629,514 | $1.1M | $8.8M | $3.4M |
| Capital expenditure | — | $3,244 | $2,776 | — | — |
| Free cash flow | — | -$11.2M | -$8.1M | — | — |
| Share repurchases | — | — | — | $300,000 | — |
| Impairments | — | — | — | $7.3M | $0 |
Shares outstanding 2.8M · Free float 24.0%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.